What is the recommended evaluation and management for a breast cancer patient presenting with palpitations and dizziness?

Evaluation and Management of Palpitations and Dizziness in Breast Cancer Patients

A breast cancer patient presenting with palpitations and dizziness requires immediate ECG with QTc measurement, followed by cardiology consultation (preferably cardio-oncology specialist), cardiac biomarkers (troponin, BNP/NT-proBNP), and echocardiography with LVEF assessment to evaluate for chemotherapy-induced arrhythmias, cardiotoxicity, or autonomic dysfunction 1, 2.

Initial Diagnostic Workup

Immediate Assessment

• 12-lead ECG with QTc measurement is the gold standard first test 1, 2

  • Stop any QT-prolonging chemotherapy agents if QTc >500 ms 1
  • Look specifically for bradyarrhythmias, heart block, atrial fibrillation, or ventricular arrhythmias

• Cardiac biomarkers: Obtain troponin (TnI or TnT) and BNP/NT-proBNP 2

  • Troponin elevation predicts future ventricular dysfunction and warrants early cardioprotective therapy 2

• Echocardiography with LVEF and global longitudinal strain (GLS) 2

  • Essential to exclude ischemic heart disease and assess for cardiotoxicity
  • Compare to baseline if available

Key Clinical Details to Elicit

• Specific chemotherapy exposure: Anthracyclines, trastuzumab, pertuzumab, or other HER2-targeted agents are high-risk for cardiotoxicity 1, 2
• Timing of symptoms: During treatment, immediately post-treatment, or years later (autonomic dysfunction can occur average 10.3 years after diagnosis) 3
• Associated symptoms: Pre-syncope/syncope suggests bradycardia or heart block; fatigue suggests autonomic dysfunction 1, 3
• Character of palpitations: Irregular heartbeat suggests arrhythmia; racing/pounding may indicate autonomic dysfunction or inappropriate sinus tachycardia 4, 3

Risk Stratification

Breast cancer patients have 10-fold increased arrhythmia burden after diagnosis, with ventricular arrhythmias being most common in advanced disease 1. Multiple mechanisms contribute:

• Chemotherapy-induced: QTc prolongation, direct myocardial toxicity, bradycardia/heart block
• Autonomic dysfunction: Affects both sympathetic and parasympathetic systems, commonly causing orthostatic hypotension (50%), inappropriate sinus tachycardia (20.8%), or POTS (12.5%) 3
• Electrolyte abnormalities: From nausea/vomiting/diarrhea, decreased oral intake 1
• Direct cardiac involvement: Tumor infiltration (rare but possible)

Management Algorithm

If Life-Threatening Arrhythmia Identified

For Torsades de Pointes (TdP):

• Administer 2g IV magnesium immediately regardless of serum magnesium level 1
• Non-synchronized defibrillation if hemodynamically unstable
• Overdrive pacing (90-110 bpm) or IV isoproterenol if pacing unavailable 1
• Correct all electrolyte abnormalities and discontinue QT-prolonging medications 1

For Symptomatic Bradycardia/Heart Block:

• Junctional escape rhythm: Pacemaker only if symptomatic 1
• Ventricular escape rhythm: Requires pacemaker implantation (unstable) 1
• Consider temporary pacemaker if active infection present 1
• Isoproterenol can maintain higher heart rates as bridge 1

If Cardiotoxicity Suspected (LVEF Changes or Troponin Elevation)

Mandatory cardiology consultation (preferably cardio-oncology specialist) 2

Initiate cardioprotective therapy 2:

• ACE inhibitors or ARBs (first-line, strongest evidence for preventing progression)
• Beta-blockers (carvedilol preferred, shown to prevent anthracycline-induced cardiomyopathy)
• Consider statin if concomitant coronary disease

For patients on anthracyclines with LVEF 40-50% or ≥10% drop:

• Cardiac biomarkers after each anthracycline dose 2
• Repeat LVEF after alternate doses 2
• Consider dexrazoxane or liposomal doxorubicin for future doses 2

For patients on trastuzumab with LVEF 40-50% or ≥10% drop:

• Monthly cardiac biomarkers and periodic cardiac exams 2
• Repeat LVEF in 3-6 weeks if trastuzumab stopped 2
• Can resume trastuzumab if LVEF normalizes to >50% 2

If Autonomic Dysfunction Suspected

Refer for autonomic reflex testing if symptoms include 3:

• Orthostatic dizziness
• Inappropriate tachycardia
• Syncope/pre-syncope
• Palpitations with postural changes

Common findings include orthostatic hypotension, inappropriate sinus tachycardia, or POTS, which respond to targeted treatment 3.

Monitoring Strategy

• If ambulatory monitoring needed: 24-48 hour Holter monitor if ECG non-diagnostic 5
• Ongoing surveillance: Continue cardiac biomarkers and LVEF assessments per chemotherapy protocol 2
• Do not dismiss symptoms: 84% of breast cancer survivors who reported palpitations to providers received cardiac testing, with 46% having new arrhythmias or cardiac abnormalities diagnosed 4

Critical Pitfalls to Avoid

1. Do not normalize or dismiss palpitations - 16% of patients report their providers dismissed symptoms, yet testing frequently reveals significant pathology 4
2. Do not delay cardiology referral - Early intervention with cardioprotective therapy prevents progression to heart failure 2
3. Do not assume benign etiology - Cancer patients have substantially higher risk of serious arrhythmias than general population 1
4. Do not forget baseline comparison - Always compare current LVEF/biomarkers to pre-chemotherapy baseline 2

Minor troponin elevation without substantial LV dysfunction does not require permanent discontinuation of anticancer therapy - instead, add cardioprotective therapy with close cardiac surveillance 2.